Evidence mapPaperPMID 41845511Full record

ReviewJournal of ovarian research2026

Critical roles of Hedgehog signaling pathway in regulating the multidrug resistance of ovarian cancer.

Ruixue Bi, Xiangyu Dong, Bingjie Cui, Hongliang Dong, Cuilan Liu, Weiwei Chen, Jianwei Liu, Zhiqiang Liu, Jing Du, Fei Wang

Abstract readReview
In one paragraph

Review in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ruixue BiDepartment of Gynecology, Binzhou Medical University Hospital, Binzhou, 256600, People's Republic of China.
Xiangyu DongDepartment of Thoracic Surgery, Binzhou Medical University Hospital, Binzhou, 256600, People's Republic of China.
Bingjie CuiMedical Research Center, Binzhou Medical University Hospital, Binzhou, 256600, People's Republic of China.
Hongliang DongMedical Research Center, Binzhou Medical University Hospital, Binzhou, 256600, People's Republic of China.
Cuilan LiuMedical Research Center, Binzhou Medical University Hospital, Binzhou, 256600, People's Republic of China.
Weiwei ChenMedical Research Center, Binzhou Medical University Hospital, Binzhou, 256600, People's Republic of China.
Jianwei LiuDepartment of Thoracic Surgery, Binzhou Medical University Hospital, Binzhou, 256600, People's Republic of China.
Zhiqiang LiuDepartment of Gynecology, Binzhou Medical University Hospital, Binzhou, 256600, People's Republic of China. byfylzq2018@163.com.
Jing DuDepartment of Gynecology, Binzhou Medical University Hospital, Binzhou, 256600, People's Republic of China. djedith@bzmc.edu.cn.
Fei WangMedical Research Center, Binzhou Medical University Hospital, Binzhou, 256600, People's Republic of China. nkuflyking@163.com.

Funding

Double-Hundred Project and Taishan Scholarship WSR2023085Ministry of Education "Chunhui" plan international cooperation project HZKY20220459National Natural Science Foundation of China 82373097National Natural Science Foundation of China 82403299Natural Science Foundation of Shandong Province ZR2019MC026Natural Science Foundation of Shandong Province ZR2022MH305Natural Science Foundation of Shandong Province ZR2023QH080Young Innovation Teams of Universities in Shandong Province 2024KJN003Young Talent of Lifting engineering for Science and Technology in Shandong, China SDAST2025QTA006
6 · The paper itself

Abstract

Ovarian cancer (OC) is a life-threatening disease with high morbidity and mortality rates among women. Treatment inevitably requires the use of multiple drugs, including platinum-based agents, taxanes, and targeted therapies, across all stages and subtypes. However, multidrug resistance frequently develops, resulting in poor prognosis and recurrence. Exploring the mechanisms of this resistance and identifying methods to restore drug sensitivity have become urgent. Current research indicates that the Hedgehog (Hh) signaling pathway is associated with the development of tumor stemness and is closely linked to the emergence of multidrug resistance in OC. However, the specific mechanisms by which Hh signaling contributes to multidrug resistance and how this pathway can be effectively targeted to restore drug sensitivity remain insufficiently understood. This article systematically summarizes the major forms of drug resistance in OC and elucidates the roles and mechanisms of the Hh pathway in multidrug resistance. These include cell stemness, spheroid formation, tumor microenvironment changes, drug efflux and metabolism, DNA damage repair, and epithelial-mesenchymal transition. Additionally, the changes in multidrug resistance-related signaling pathways caused by Hh were reviewed. Finally, we discussed strategies to sensitize OC by targeting the Hh pathway in combination with chemotherapy or targeted drugs. This approach represents a promising strategy to overcome multidrug resistance in OC.

Indexed as

Drug Resistance, MultipleDrug Resistance, NeoplasmHedgehog ProteinsOvarian NeoplasmsSignal TransductionAnimalsAntineoplastic AgentsEpithelial-Mesenchymal TransitionFemaleHumansNeoplastic Stem CellsAntineoplastic AgentsHedgehog ProteinsCombination therapyGLI1HedgehogMultidrug resistanceOvarian cancer

Identifiers

PMID41845511
PMCPMC13107841

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.